Physician profile
Shilpy Kanda
NPI 1477060499
$1,028.74
in general payments reported to CMS, 2019-2025
24 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $107 · 2023: $113 · 2024: $150 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $124.94 | 2021 | |
| Merck Sharp & Dohme LLC | $115.75 | 2021-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sobi, INC | $94.93 | 2021-2024 | |
| Verrica Pharmaceuticals INC. | $86.74 | 2024 | Ycanth |
| Seqirus USA INC | $69.39 | 2021-2024 | Flucelvax Quadrivalent, Flucelvax |
| Novo Nordisk INC | $56.97 | 2025 | |
| Glaxosmithkline, LLC. | $47.75 | 2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $36.72 | 2025 | Breztri |
| Xeris Pharmaceuticals, INC. | $36.57 | 2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $34.95 | 2022-2025 | Mounjaro, Zepbound |
| Ucb, INC. | $29.92 | 2025 | Briviact |
| Sanofi Pasteur INC. | $29.70 | 2021-2022 | |
| Edwards Lifesciences Corporation | $29.50 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $29.04 | 2025 | Otezla, Repatha |
| Abbott Laboratories | $28.78 | 2025 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $28.31 | 2025 | Talicia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.04 | 2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $25.13 | 2023 | |
| Corcept Therapeutics | $18.68 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $17.42 | 2025 | |
| Atricure, INC. | $16.14 | 2022 | |
| Phadia US INC. | $15.48 | 2023 | Immunocap |
| Abbvie INC. | $15.21 | 2022 | |
| Cranial Technologies, INC | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpy Kanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.